Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.2%

12 terminated/withdrawn out of 107 trials

Success Rate

87.9%

+1.3% vs industry average

Late-Stage Pipeline

11%

12 trials in Phase 3/4

Results Transparency

70%

61 of 87 completed trials have results

Key Signals

3 recruiting61 with results9 terminated

Enrollment Performance

Analytics

Phase 1
65(66.3%)
Phase 2
19(19.4%)
Phase 3
10(10.2%)
N/A
2(2.0%)
Phase 4
2(2.0%)
98Total
Phase 1(65)
Phase 2(19)
Phase 3(10)
N/A(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (107)

Showing 20 of 107 trials
NCT07758985Phase 1Recruiting

Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.

Role: lead

NCT05874271Not ApplicableCompleted

Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea

Role: collaborator

NCT04825782Completed

MiMBa Pregnancy Registry

Role: collaborator

NCT07011511Phase 1Recruiting

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

Role: lead

NCT05690841Phase 3Recruiting

FocaL Mass Drug Administration for Vivax Malaria Elimination

Role: collaborator

NCT06558643Phase 1Completed

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

Role: lead

NCT07548021Phase 1Not Yet Recruiting

Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda

Role: lead

NCT05361486Completed

Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

Role: lead

NCT06806956Enrolling By Invitation

Severe Malaria in Remote Areas- Closing the Evidence Gap

Role: collaborator

NCT05085340Completed

MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention

Role: collaborator

NCT07362498Completed

Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya

Role: collaborator

NCT05879224Not ApplicableCompleted

Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia

Role: collaborator

NCT04300309Phase 2Terminated

Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Role: collaborator

NCT05979207Phase 1Completed

Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Role: lead

NCT04532931Phase 2Completed

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Role: collaborator

NCT05287893Phase 1Completed

Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

Role: lead

NCT05930782Phase 1Completed

Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.

Role: lead

NCT05507970Phase 1Completed

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Role: lead

NCT05205941Phase 1Completed

MMV533 Plasmodium Falciparum Volunteer Infection Study

Role: lead

NCT04323306Phase 1Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

Role: lead